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Abstract
 Objectives—The prevalence of depression is high in patients with Crohn’s Disease (CD). We 
examined the influence of affective-cognitive symptoms of depression on the risk of exacerbation 
of CD.
 Methods—We studied 2144 adult volunteers with a self-reported diagnosis of CD who 
completed a baseline survey that included demographics, CD status and an affective-cognitive 
index of depression. Linear and logistic regression analyses were used to determine if CD status at 
12 months was associated with the baseline measure of depression. Analyses were adjusted for 
confounders including age, gender, race, baseline disease activity, disease duration, prior 
hospitalization and surgery, corticosteroid and anti-TNF use, medication adherence, BMI, current 
smoking, education, and sleep quality.
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 Results—Depression was significantly associated with subsequent increases in SCDAI score 
in both unadjusted (p<0.001) and adjusted (p< 0.001) analyses. This association was non-linear, 
with a shallower slope for lower levels of depression. A 10 point increase in depression t-scores 
from 55 to 65 was associated with a 18.6 point increase in SCDAI (95% CI 11.5–25.6) and an 
odds ratio of 1.27 for SCDAI > 150 at follow up (CI: 1.01–1.60). We also found a significant 
association between depressive symptoms and hospitalization.
 Conclusion—Cognitive-affective depressive symptoms were significantly associated with a 
risk of exacerbation of CD and hospitalization.
 INTRODUCTION
Crohn’s disease (CD) is a chronic bowel condition affecting more than 700,000 people in 
North America (1). CD is characterized by episodes of exacerbations and remissions. 
Because the course is unpredictable and there is no cure, disease management must focus on 
achieving and maintaining remission, preventing complications, improving quality of life 
and minimizing the impact of comorbid conditions.
The rates of depression among CD patients appear to be higher (2) than the general 
population. The key question is whether depression influences the manifestation and severity 
of CD or if depression is a consequence of suffering from a debilitating chronic disease. 
Therefore, the aim of this study was to determine whether there is a relationship between 
depressive symptoms and subsequent CD activity.
Earlier cohort studies reporting comorbidity of CD and patients’ mood used depression 
measures that include physical symptoms that overlap with those seen in CD such as 
disordered sleep, fatigue and poor appetite (3, 4). To eliminate the overlap and avoid the 
possibility of spurious relationships between measures of exposure and outcome, this study 
restricts the ascertainment of depression to one dimension of depression, affective-cognitive 
symptoms. It is yet unclear which symptom dimensions of depression are associated with 
CD activity and this will be the first study with adult CD patients of the relationship between 
a specific symptom dimension of depression and later CD activity. Different subsets of 
depressive symptoms have been investigated with adolescents with IBD (5). The principal 
hypothesis for this study is: CD patients experiencing affective-cognitive symptoms of 
depression at baseline were more likely to report active CD 12 months later. A secondary 
hypothesis is that CD patients experiencing affective-cognitive symptoms of depression at 
baseline will have more frequent hospitalizations, surgeries, and anti-TNF (anti- Tumor 
Necrosis Factor) usage to treat their CD because of a more severe or persistently active CD.
 METHODS
 Study Population
Subjects were volunteers in CCFA Partners, an internet-based cohort study sponsored by the 
Crohn’s and Colitis Foundation of America (CCFA). This cohort has been described in 
detail in previous publications (6). In brief, CCFA Partners is a longitudinal Internet-based 
cohort of volunteers with self- reported inflammatory bowel disease. Participants had been 
invited to participate in the cohort through the CCFA e-mail roster, social media, and at 
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educational events. During the first recruitment volunteers were excluded if they were under 
age 18 and those who did not have self-reported IBD (CD, UC, or indeterminate colitis). 
Volunteers also had to have Internet access to join the e-cohort and complete the surveys. 
There were no other exclusion criteria for participation. All volunteers completed a baseline 
survey comprising demographics and information about their IBD. Optional modules on 
various patient reported outcomes were included with the baseline survey. Volunteers were 
invited to complete a follow-up questionnaire every 6 months to report disease activity, 
changes in the treatment and repeated measures of patient reported outcomes. The study 
protocol was approved by the Institutional Review Board at the University of North 
Carolina, Chapel Hill, North Carolina and Vanderbilt University, Nashville TN.
 Instruments
For this study, all volunteers completed a depression symptom questionnaire (PROMIS) (7) 
that measured exposure and a CD symptom questionnaire (SCDAI) (8) at baseline and 12 
months later that measured outcome.
Depression was measured by using the National Institutes of Health Patient Reported 
Outcomes Measurement Information Systems (PROMIS) depression 4-item short form (7). 
In validation studies the PROMIS depression test bank items correlated with the Center for 
Epidemiological Studies Depression Scale, r= 0.83. The PROMIS depression questionnaire 
used in this study did not include items assessing somatic symptoms that overlap with 
symptoms of CD such as poor sleep, fatigue and lack of appetite. The short form was 
composed of four Likert-type five point items measuring the frequency of negative mood (I 
felt depressed) and cognition: (negative beliefs about the self (I felt worthless, I felt 
helpless), decreased life engagement/negativity to the future (I felt hopeless) during the 
previous seven days. It was administered at baseline and follow up. All responses were 
summed to form a raw score ranging from 4 to 20, which was then converted to a 
standardized score (t-score). For all PROMIS measures the t-score for the standardizing 
population is 50 with a standard deviation equal to 10. Thus, a t-score change from 55 to 65 
represents a change from 0.5 standard deviations to 1.5 standard deviations above the 
standardizing population mean.
Disease activity at baseline and the 12-month follow up was assessed by the Short Crohn’s 
Disease Activity Index (SCDAI) (8). Disease activity was modeled as both a continuous 
SCDAI t-score and a binary outcome with active disease being defined as a SCDAI t-score 
greater than 150. The SCDAI was developed to provide a shortened and simplified Crohn’s 
Disease Activity Index (CDAI) using a patient’s self-report. We considered any abdominal 
surgeries within 12 month, any hospitalizations within 12 months, and use of anti-TNFs at 
12 months as secondary outcomes because these medical interventions are often associated 
with greater CD activity.
 Covariates
Based on the research literature, the following variables were included in the regression 
models as potential confounders of the association between depression and CD activity: age, 
gender, race, baseline SCDAI, disease duration, anti-TNF use, BMI, current smoking, level 
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of educational attainment, and sleep (9). For the anti-TNF outcome, we also adjusted for 
baseline anti-TNF usage. Post-hoc analyses were conducted where we additionally adjusted 
for baseline history of hospitalization/surgery, use of steroids, and adherence to oral 
medications (10) to confirm our findings.
 Statistical Analysis
Continuous variables were summarized using the median, 25th, and 75th percentile, and 
categorical variables were summarized using percentages in each category. The Kruskal-
Wallis test (continuous variables) and Pearson’s chi-square tests (categorical variables) were 
used to compare baseline covariates by depression t-score quartile.
In this prospective cohort study we represented baseline disease activity as continuous 
instead of as a dichotomized variable – active versus inactive - as advocated by 
methodologists (11, 12). Use of baseline disease activity as a continuous variable allowed us 
to operate without any assumptions about the shape of the relationship, use all the 
information about disease activity at hand and allowed us to detect any non- linearity in the 
relation between exposure (depressive symptoms) and outcome (CD activity).
Linear regression was used to model continuous outcomes and logistic regression was used 
to model binary outcomes. From the linear regression models, we report the adjusted 
expected change in mean SCDAI at 12 months per 10 point increase in baseline depression. 
From the logistic regression models, we report the odds ratio for having active disease 
(defined as SCDAI >150) per 10 point increase in baseline depression t-score. We pre-
specified that depression would be flexibly modeled as a continuous predictor while making 
minimal assumptions about the form of the relationship between depression symptoms and 
the outcome. This was accomplished by modeling depression using a restricted spline (3 
d.f.).
Based on the results of the linear regression analysis of SCDAI, we found that the slope for 
the depression t-score changed at 55, being flatter below 55 and steeper above 55. We report 
our results from all regression models in reference to 10-point changes in depression t-score 
using intervals of 45 to 55, 55 to 65, and 65 to 75. Statistical significance of the depression 
construct was assessed using 2 d.f. Wald tests to simultaneously test each of the depression 
coefficients included in the regression model.
Sensitivity analyses were also conducted where we treated depression t-score as a 
continuous variable, but without using restricted cubic splines to flexibly model the 
association. Logistic models were estimated with the primary and secondary outcomes. For 
these models, we report the unadjusted and adjusted association of a 10-point increase in 
depression t-score with each outcome. Confounding was evaluated by looking for a 10% 
change in the estimated regression coefficient for depression t-score.
 RESULTS
A total of 5707 subjects with CD completed baseline surveys, 2144 of whom also completed 
a 12-month follow up SCDAI. Volunteers without 12 month follow up surveys were younger 
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(median age 40 versus 43 years), less likely to be white (92% versus 95%), more likely to be 
current smokers (12% versus 7%), less educated (65% college and above versus 73%) and 
likely to be more depressed (median t-score 52.7 +/− 10.0 versus 51.4 +/− 9.2). There was 
no evidence that duration of diagnosis, sex, BMI, or sleep scores differed between analyzed 
(N=2144) and lost to follow (N=3775) subjects. Table 1 shows the distribution of patient 
characteristics by extent above or below a depression t-score score of 50. Respondents with 
the most severe depressive symptoms at baseline were younger, more recently diagnosed 
with CD, were smokers, were heavier and reported lower levels of educational attainment.
 Association between baseline depression and 12-month SCDAI and secondary 
outcomes
We found a significant association between depression t-score and subsequent SCDAI score, 
controlling for baseline differences in SCDAI score, in both unadjusted (p<0.001) and 
adjusted (p<0.001) linear regression models. Furthermore, we found this relationship to be 
curved with a shallower slope below 55 and a steeper slope above 55. Figure 1 depicts this 
association by plotting the expected SCDAI versus depression t-score while adjusting for 
other covariates by fixing continuous covariates at their mean and categorical covariates at 
their mode. Adjusting for covariates, a 10 point increase in depression t-score from 55 to 65 
was associated with a 18.6 point increase in SCDAI (95% CI: 11.5 to 25.6). A 10 point 
increase in depression t-score from 45 to 55 was only associated with a 6.9 point increase 
(95% CI: 2.4 to 11.4) in SCDAI.
There was also a significant association between elevated depression t-score and the odds of 
reporting active CD 12 months later in both unadjusted and adjusted logistic regression 
models. Figure 2 summarizes the odds ratios from the adjusted models for 10 point increases 
in baseline depression t-score for the primary and secondary outcomes. Because we used 
regression splines to flexibly model the association between depression t-score and each 
outcome, a 10-point increase in depression t-score was not constrained to be the same for all 
10-point increases. In Figure 2, we present the odds ratios associated with changes from 45 
to 55, 55 to 65, and 65 to 75 in t-score. For SCDAI > 150, the odds ratios for a change from 
55 to 65 and 65 to 75 (OR=1.27,95% CI 1.01–1.60, and OR=1.29, CI 95% 0.97–1.72, 
respectively) were larger than the odds ratios for a change from 45 to 55 (OR=1.18, 95% CI 
1.01–1.37) in depression t-score. Overall, there was a significant association between 
baseline depression t-score and the odds of active CD (p=0.001, df=2). Hospitalizations 
were also significantly associated with depression t-score in adjusted models (p=0.03, df=2) 
and the odds ratios were similar for increases from 45 to 55, 55 to 65, and 65 to 75. There 
was no evidence that abdominal surgeries (p=0.34, df=2) or anti-TNF drugs (p=0.15, df=2) 
were associated with depression t-score when depression was modeled flexibly using 
splines.
 Supplemental Analyses
Supplemental analyses were conducted to further scrutinize the conclusions from our 
primary model. For these analyses we treated depression t - scores as a continuous variable, 
but without using restricted cubic splines to flexibly model the association. Logistic models 
were estimated for the primary and secondary outcomes, and we computed the unadjusted 
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and adjusted associations of a 10-point increase in depression t - score with each outcome. 
We also conducted an additional analysis where we adjusted for medication adherence 
scores, baseline history of hospitalization/surgery, use of steroids, and our other previously 
included confounders. In the 1285 participants for whom the medication adherence score 
was available, we observed similar, albeit slightly stronger association between baseline 
depression and disease activity at 12 months. There was also no evidence of residual 
confounding based upon our approach utilizing a 10% change in the estimated regression 
coefficient for depression t - score.
 DISCUSSION
Depression is a common comorbidity for patients with CD (2). Depression impacts on the 
quality of patients’ lives (13), cost of treatment (14), adherence to disease management (15) 
and may even alter the biologic potential for controlling the status of the disease (16). 
Hence, we hypothesized that comorbid depressive symptoms in adults with CD would 
predict higher levels of CD activity a year later. We tested this hypothesis prospectively 
using validated measures of depressive symptoms (exposure) and CD activity (outcome). 
Controlling for confounding variables, the CD volunteers who reported higher levels of 
depressive symptoms had a greater odds of reporting more frequent diarrhea, pain and 
reduced well-being 12 months later than less depressed CD volunteers. Further, CD 
volunteers with more severe depressive symptoms subsequently reported higher odds of 
hospitalization but not surgery or anti-TNF usage.
Our study supports the findings of earlier cohort studies showing that depression is 
associated with subsequent CD activity (3, 4, 17), suggesting a temporal relationship 
between depression and subsequent CD activity. However, what is unique about this study is 
the finding that the association between depression and subsequent CD activity is stronger 
when there are higher levels of baseline depressive symptoms, suggesting a dose response 
relationship. Heightened depression, especially the cognitive characteristic of negativity to 
the self and the future as studied in this study, maybe a psychological condition that 
influences CD morbidity through physiological processes and indirectly via behavioral 
pathways. The health risk behaviors and psychobiological changes associated with 
depression increase the risk for chronic medical disorders, and biological changes and 
complications associated with chronic medical disorders may precipitate depressive episodes 
(18). For example, the CD volunteers who reported greatest negativity to the self and the 
future and sadness at baseline were also more likely to be smokers who were overweight and 
less educated. Controlling for these factors attenuated the effect estimates but they remained 
significant. More needs to be known about depressed mood and negativity toward the self 
and the future in terms of associated eating patterns, medication use and adherence and 
physical activity in order to understand how the affective-cognitive dimension of depression 
influences health risk behavior and the immune system of depressed CD volunteers. 
Depression and its symptom dimensions are now being investigated in depressed chronic 
disease patients with myocardial infarction (19) and diabetes (20). For example, study of the 
effects of depressive symptoms on immunological parameters in heart failure patients (21) 
showed that the level of cognitive/affective depression at baseline was positively associated 
with hsCRP (high sensitivity C Reactive Protein), sTNFR1 and sTNFR2 (Tumor Necrosis 
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Factor soluble receptors) at 12-month follow up, while somatic/affective depression at 
baseline was positively associated with sTNFR1 and sTNFR2.
While there is consistency in the findings across the limited number of cohort studies of CD 
and comorbid depression, the previous studies were conducted under very different 
conditions. Our study had methodological advantages from prior investigations. Our cohort 
study was not limited to a tertiary referral center and is the first to our knowledge to 
eliminate the influence of overlapping somatic symptoms of depression and CD on the 
results. In previous cohort studies of comorbid CD and depression, depression was treated as 
a homogenous construct without regard to the varied symptoms of depression (3, 4, 17). It is 
possible that these earlier cohort studies of depression and CD may have demonstrated 
correlation because the somatic symptoms of depression may be more strongly linked to the 
mechanisms thought to underlie the depression-CD relationship (22). Another advantage of 
the present study was the use of CD activity level as a continuous variable at baseline instead 
of the more typical dichotomization which results in reduced power. This allowed for the 
detection of possible non-monotonic relationships between symptoms of depression and CD 
activity level. Our findings, therefore, provide more definitive data demonstrating that higher 
levels of affective-cognitive symptoms of depression are associated with subsequent 
increased disease activity and need for hospitalization even after controlling for known 
confounders.
There are limitations that need to be acknowledged. First, we have explored the relationship 
of depressive symptoms and CD in a large internet based cohort of CD patients. The 
sampling introduced volunteer self-selection, resulting in a cohort composed largely of 
Caucasian women who took fewer health risks and were less depressed and reported less 
active disease at the baseline. The study thus may under-represent individuals who might 
show the hypothesized relationship. Although the prospective study design with appropriate 
control for a number of potential confounders provides a high degree of internal validity, 
attrition was extremely high in this study with a loss to follow up of 62%. Analysis of the 
differences between those CD volunteers who completed the 12 month follow up SCDAI 
and those who did not demonstrated that the non-responders had higher t-score on the 
depression measure. However, this difference in mean t-scores was only 1.3 which, while 
significant, is below the threshold of a minimal important difference for this measure. In 
addition, in using the four item PROMIS abbreviated depression scale we did not allow a 
direct comparison of different symptom dimensions of depression including affective-
cognitive and affective-somatic symptoms in the prediction of subsequent CD activity level. 
Although we do not know if the CD volunteers had been treated with antidepressant 
medication or psychotherapy, in reality, that information is not relevant to the association 
between affective-cognitive depressive symptoms and the SCDAI. Finally, The SCDAI is a 
patient reported measure of disease symptoms, rather than a direct measure of intestinal 
inflammation. Hence, we cannot fully evaluate a direct causal relationship between 
symptoms of depression and increased mucosal inflammation. As such, we encourage future 
research on comorbid depression and CD activity using measures of inflammation to help 
elucidate the full impact of depressive symptoms on inflammatory processes. However, 
given recently increasing interest in patient-reported outcomes research, our results 
Gaines et al. Page 7
Am J Gastroenterol. Author manuscript; available in PMC 2016 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
contribute to improved understanding of the role of depression in predicting which patients 
maybe more likely to experience symptoms of increased CD activity.
Although use of the study’s longitudinal design suggests that affective-cognitive symptoms 
of depression are antecedent to CD activity twelve months later, both CD and depressive 
symptoms have potentially long induction periods making it difficult to establish the precise 
period “at risk”. This raises possible concern about reverse causality, with earlier CD activity 
influencing the incidence of depressive symptoms rather than the converse. In order to 
clarify the sequencing of depressive symptoms and CD activity and understand their 
dynamic interaction, longitudinal panel data will be helpful. Measures of depression 
(exposure) must include both cognitive and somatic symptoms of depression and their 
interaction over time. Crohn’s disease activity (outcome) must be measured by objective 
methods, such as fecal calprotectin, and from patients’ symptom appraisals, and for longer 
periods and with shorter exposure- outcome intervals before coming to valid conclusions 
about the temporal relationship between CD activity and symptom dimensions of 
depression.
The present study expands and informs the field in two very important ways. The first is that 
it suggests that CD patients who also have affective-cognitive symptoms of depression are 
more likely to have more severe CD symptoms later in time. The second is that it starts to 
chart the map for future research about comorbid depression and CD, starting with the 
examination of possible reverse causality, the assessment of measurement invariance, and 
possible health behavior and immunological mediators of the relationship of depressive 
symptoms and CD activity. In the present time, however, even without complete 
understanding of causality or mechanism, this observation about comorbid depression and 
subsequent CD activity and hospitalizations makes a strong case for routine assessment of 
depression when evaluating and treating CD. Depressive symptoms comorbid with CD seem 
to add to the cost of treatment and are associated with lower quality of life and poorer 
clinical outcomes. Management of depression should be integral to the management of CD 
patients.
Negativity to the self and the future and depressed affect as measured here may represent 
adaptational difficulties which could influence self-management, the immune system and 
ultimately disease progression (20). Given the substantial challenges that result from 
exacerbations of CD, gastroenterologists need to be alert to depression in CD patients and 
refer for appropriate management.
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Study Highlights
What is current knowledge?
Rates of depression among CD patients is higher than the general 
population
Clinic-based cohort studies show that depression predicts subsequent CD 
activity
Prior studies of CD and depression assume all depression symptoms are 
roughly equivalent
What is new here?
Affective-cognitive symptoms of depression predicted subsequent CD 
activity and hospitalization rate, suggesting a temporal relationship
CD activity is greater with baseline higher levels of affective-cognitive 
symptoms, suggesting a dose-response relationship
Symptom dimensions of depression maybe important in understanding the 
association of depression and self-reported CD activity
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Figure 1. 
Association between baseline depression t-score and SCDAI at 12 month follow up with 
95% confidence interval. Depression t-score was modeled flexibily using restricted cubic 
splines to allow for a curved relationship. SCDAI is estimated from a multivariable model 
and represents an average subject with a baseline SCDAI of 150, sleep t-score of 50, length 
of diagnosis 15 years, white race, non-current smoker, 42 years old, BMI of 26, and college 
education.
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Figure 2. 
Adjusted fold increase in the odds of SCDAI above 150, hospitalizations, abdominal 
surgery, and anti-TNF usage per 10 point increase in depression t-score. Depression t-score 
was flexibly modeled using restricted cubic splines to allow for different odds ratio for a 45 
to 55, 55 to 65, and 65 to 75 point increase in t-score.
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